CURRENT PHARMACEUTICAL BIOTECHNOLOGY, vol.17, no.14, pp.1231-1245, 2016 (SCI-Expanded)
Background: Despite development of novel cancer drugs, invasive ductal breast carcinoma and its metastasis are still highly morbid. Therefore, new therapeutic approaches are being developed and Hsp90 is an important target for drug design. For this purpose, a series of benzodiazepine derivatives were designed and synthesized as novel Hsp90 inhibitor.